Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Neuroimmune Pharmacology"
DOI: 10.1007/s11481-020-09937-4
Abstract: Fingolimod reduces inflammatory activity in multiple sclerosis (MS) by acting as a functional antagonist of sphingosine 1-phosphate (S1P) receptors. It has been suggested that S1P might also contribute to the antiatherogenic effect of high-density lipoprotein… read more here.
Keywords: lipid profile; fingolimod treatment; treatment; profile alterations ... See more keywords
Peripheral T cell lymphoma not otherwise specified induced by fingolimod treatment for multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz343.016
Abstract: Abstract Introduction Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator that prevents B and T lymphocyte egress from the lymph nodes, and reduces peripheral lymphocyte counts and entry of lymphocytes into the central nervous system. In… read more here.
Keywords: fingolimod treatment; treatment; induced fingolimod; multiple sclerosis ... See more keywords
Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2023 at "Biomolecules"
DOI: 10.3390/biom13020331
Abstract: Alzheimer’s disease (AD) is the most common cause of dementia. Fingolimod has previously shown beneficial effects in different animal models of AD. However, it has shown contradictory effects when it has been applied at early… read more here.
Keywords: sex dependent; fingolimod treatment; alzheimer disease; time sex ... See more keywords